What question did this study set out to answer?

Review the molecular mechanisms of cardiotoxicity from targeted breast cancer therapies and identify clinical and genetic tools for risk stratification and cardiac prevention.

December 14, 2010The BreastOpen Access

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

View Full Paper

Ask AI

Bookmark

Population

Breast cancer patients receiving targeted therapies

Design

Review

Authors

AZAlberto ZambelliOspedale Papa Giovanni XXIII MPMatteo Giovanni Della PortaHumanitas University EEErmanno EleuteriIstituti Clinici Scientifici Maugeri

Discussion

Member takes

Implication

Supports integrated cardio-oncology care; leaves open prospective validation of genetic risk tools.

Key Points

Review the molecular mechanisms of cardiotoxicity from targeted breast cancer therapies and identify clinical and genetic tools for risk stratification and cardiac prevention.
Synthesized mechanistic and clinical evidence on targeted agents, including anti-ERBB2 treatments (trastuzumab, lapatinib), VEGF inhibitors (bevacizumab), and tyrosine-kinase inhibitors (sorafenib, sunitinib).
Evaluated molecular survival pathways in cardiomyocytes and endothelial cells alongside genetic biomarkers, such as ERBB2 gene polymorphisms, for patient risk stratification.
Targeted breast cancer therapies induce cardiotoxicity by abrogating physiological pathways essential for cardiomyocyte and endothelial cell survival and proliferation.
Genetic profiling of ERBB2 polymorphisms offers predictive utility to identify patient subgroups at elevated risk for drug-induced heart failure.
Minimizing cardiac complications requires tailored drug combinations and an integrated partnership between oncologists and cardiologists for close longitudinal monitoring.

Structured PICO

Population

Breast cancer patients receiving targeted therapies

Intervention

Targeted therapies including anti-ERBB2 treatment (Trastuzumab, Lapatinib), VEGF inhibitors (Bevacizumab), and tyrosine-kinase inhibitors (Sorafenib, Sunitinib)

Outcome

Cardiotoxicity and heart failuresafety

This review highlights the mechanisms, prediction, and prevention of cardiotoxicity induced by targeted therapies in breast cancer, emphasizing the need for close collaboration between cardiologists and oncologists.

Cite This Study

Zambelli et al. (2010) studied this question.

synapsesocial.com/papers/6a709d59abc331a858079cad https://doi.org/10.1016/j.breast.2010.11.002

Topics

Women and heart disease Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider